Biovica secures $85,000 work order for oncology study
Biovica received its first work order under a new Master Services Agreement, valued at about USD 85,000, to cover DiviTum TKa testing in a first-in-human Phase 1 study of an oral next-generation CDK inhibitor. Testing will be run at Biovica’s Sweden laboratory for a study initially recruiting patients outside the US.